Trial Profile
A Randomised, Double-blind, Placebo-controlled Phase II Study, Comparing the Efficacy and Safety of Inhaled SNG001 to Placebo Administered to Asthmatic Subjects After the Onset of a Respiratory Viral Infection for the Prevention or Attenuation of Asthma Symptoms Caused by Respiratory Viruses
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 14 Dec 2021
Price :
$35
*
At a glance
- Drugs Interferon beta-1a (Primary)
- Indications Asthma
- Focus Biomarker; Pharmacodynamics; Proof of concept; Therapeutic Use
- Sponsors Synairgen
- 07 Dec 2021 According to Synairgen media release, data from this study presented as oral presentation at the 8th European Scientific Working Group in Influenza (ESWI) Influenza Conference.
- 07 Dec 2021 Results published in the Synairgen Media Release
- 18 Jul 2013 Biomarker results will be presented at the 23rd Annual Congress of the European respiratory Society (ERS-2013) according to a Synairgen media release.